Nanosilica-supported liposome (protocells) as a drug vehicle for cancer therapy

This study encompasses the development and comparison of nanosilica-supported liposome (protocells), conventional liposome, and polyethylene glycol (PEG)-liposome. An effort was made to study the drug encapsulation efficiency and the in vitro release of the drug, and whether protocells (nanovesicles) could sustain the release of the drug by increasing the residence time, which could reduce the dose-related systemic toxicity of the drug, that is, vincristine sulfate. Nanovesicles had a good encapsulation efficiency (71%), which was comparable to the conventional and PEG-liposome, which were 74% and 78%, respectively. The obtained vesicles were in the size range 100–150 nm, and the drug release efficiency of conventional, PEGylated, and protocells liposome was about 67%, 42%, and 52%, respectively, in 150 minutes. The intermediate value of nanosilica-supported liposome indicates the ability for stable and controlled release of the drug, which prevents the rapid burst or slower release of the drug. This study reveals that protocells as nanovesicles could be a better choice for the delivery of cancer drugs such as vincristine sulfate.

• Publication year

  2018

• Venue

  International Journal of Nanomedicine

• Publication date

  2018-03-15

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.2147/IJN.S125013PMID 29593410PMCID 5863642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liposome-mesoporous silica nanoparticles fused cores: a safer mode of drug carrier.

  2011cited by this paper
• Mesoporous silica nanoparticles for intracellular controlled drug delivery.

  2010cited by this paper
• Preparation and In Vitro Evaluation of a Pegylated Nano-Liposomal Formulation Containing Docetaxel

  2009cited by this paper
• Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems.

  2007cited by this paper
• Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs.

  2007cited by this paper

• Development of Cell-Derived Plasma Membrane Vesicles as a Nanoparticle Encapsulation and Delivery System

  2025cites this paper
• Artificial cells for in vivo biomedical applications through red blood cell biomimicry

  2024cites this paper
• Development of Cell-Derived Plasma Membrane Vesicles as a Nanoparticle Encapsulation and Delivery System

  2023cites this paper
• Surface-modified cationic liposomes with a matrix metalloproteinase-degradable polyethylene glycol derivative improved doxorubicin delivery in murine colon cancer

  2023cites this paper
• Preparation and In Vitro Cytotoxicity Assessments of Spherical Silica-Encapsulated Liposome Particles for Highly Efficient Drug Carriers.

  2021cites this paper
• USE OF ARTIFICIAL CELLS AS DRUG CARRIERS.

  2021cites this paper
• Preparation of T‑2 toxin‑containing pH‑sensitive liposome and its antitumor activity.

  2020cites this paper